Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Otenabant (CP-945598) has been investigated for the treatment of Obesity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 67.00 | |
10 mg | In stock | $ 96.00 | |
25 mg | In stock | $ 183.00 | |
50 mg | In stock | $ 327.00 | |
100 mg | In stock | $ 488.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 75.00 |
Description | Otenabant (CP-945598) has been investigated for the treatment of Obesity. |
Targets&IC50 | cannabinoid:0.7 nM(Ki) |
In vitro | Otenabant HCl has a low Ki affinity for human CB2 receptors of 7.6 μM[1]. Otenabant HCl inhibits CB1 receptor with moderate unbound microsomal clearance, low hERG affinity, and adequate CNS penetration[2]. |
In vivo | Otenabant acutely stimulates energy expenditure in rats and decreases the respiratory quotient which suggests a metabolic switch to increased fat oxidation. Otenabant (10 mg/kg, p.o.) promotes a 9%, vehicle-adjusted weight loss in a 10-day weight loss study in diet-induced obese mice[1]. Otenabant HCl reverses four cannabinoid agonist-mediated behaviors (locomotor activity, hypothermia, analgesia, and catalepsy) following administration of the synthetic CB1 receptor agonist CP-55940. Otenabant HCl exhibits dose-dependent anorectic activity in a model of acute food intake in rodents and increased energy expenditure and fat oxidation[2]. |
Synonyms | CP-945598 |
Molecular Weight | 510.42 |
Formula | C25H25Cl2N7O |
CAS No. | 686344-29-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (19.59 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Otenabant 686344-29-6 GPCR/G Protein Cannabinoid Receptor CP945598 inhibit CP-945598 Inhibitor CP 945598 inhibitor